Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5668410 | 0.89 | LTA4H (0.48) | TRPV1MEN1KMT2ACACNA1GCACNA1H | |
| SCHEMBL4388997 | 0.85 | CACNA1G (0.46) | TRPV1KMT2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL2171264 | 0.83 | NPC1 (0.55) | MEN1KMT2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL5670058 | 0.83 | TRPV1 (0.45) | TRPV1MEN1KMT2ACACNA1GCACNA1H | |
| SCHEMBL2171605 | 0.83 | TRPV1 (0.58) | TRPV1MEN1KMT2ACACNA1GCACNA1H | |
| SCHEMBL5668902 | 0.83 | CACNA1G (0.44) | MEN1KMT2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL2172634 | 0.82 | TRPV1 (0.56) | TRPV1MEN1KMT2AHIF1ASLC40A1 | |
| SCHEMBL5667686 | 0.82 | CACNA1G (0.46) | TRPV1MEN1KMT2ACACNA1GCACNA1H | |
| SCHEMBL5669931 | 0.81 | ALDH1A1 (0.52) | MEN1KMT2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL2172285 | 0.81 | CACNA1G (0.45) | MEN1KMT2ACACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | TRPV1 3477/4885MEN1 3194/4885KMT2A 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.